Psoriatic ArthritisHLABLRPNCT07718815
HLA B Leader in Patients With Psoriatic Arthritis
A study testing blood test in people with Psoriatic Arthritis and HLA b Leader, run by Centre Hospitalier Universitaire, Amiens at 1 site in France.
Trial summary
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Psoriatic Arthritis, HLA b Leader, HLA B27
- What is being tested?
- blood test
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 658 participants
- Where
- 1 siteFrance
- Study dates
- 6 May 2025to Sep 2026
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- For the "Patient" group:
- Patient over 18 years of age
- Patient affiliated to a social security scheme
- Patient with psoriatic arthritis according to the CASPAR 2006 classification, followed at the CHU Amiens-Picardie.
- For the "control" group:
- Individuals over 18 years of age
Show all 9Show fewer
- Individual affiliated to a social security scheme
- Individual having agreed to participate in the study
- Individuals with no inflammatory or autoimmune diseases
Who cannot join
- Patient or control not understanding French
- Patient not included in the Amiens Picardie University Hospital's "Psoriatic Rheumatism" cohort, or control not included in the Amiens Picardie University Hospital's bone marrow donor cohort.
- Patient or control objecting to participation in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
CHU Amiens Picardie
Amiens, Picardie, 80054
Vincent GOEB, Pr, +33322668259, goeb.vincent@chu-amiens.fr
About this study
Psoriatic arthritis (PsA), a chronic immune-mediated heterogeneous inflammatory disease characterized by musculoskeletal inflammation (arthritis, enthesitis, spondylitis and dactylitis), usually occurs in patients with psoriasis. The spondyloarthritides (SPs) (of which psoriasis is one) are a group of inflammatory diseases that share an association with the HLA-B27 MHC class I molecule.
Given this association, these diseases are classically regarded as disorders of adaptive immunity.
In bone marrow donation, HLA-B exon 1 dimorphism (HLAB leader) is associated with risk of graft- versus-host disease, relapse and overall survival after unrelated hematopoietic cell transplantation (UHCT), haploidentical UHCT and cord transplantation. In the literature, there are no studies suggesting the involvement of the HLA B leader gene in MS and RPs. The main aim of this study is to compare the presence of the HLA B leader gene between a group of patients with psoriatic arthritis and a healthy group without inflammatory disease.
- Conditions
- Psoriatic Arthritis, HLA b Leader, HLA B27
- Being tested
- blood test
- Keywords
- Psoriatic arthritis, HLA b leader, HLA B27
- Medical subject headings
- Arthritis, Psoriatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood testBiological
Addition of an extra tube for blood tests (a single tube for genetic research), enabling phenotyping of the HLA B27 and HLA B leader genes.
| Study group | Role | What they receive |
|---|---|---|
| psoriatic rheumatism patient | Experimental | patients with psoriatic arthritis Receives: Biological: blood test |
| healthy group | Active comparator | patients without inflammatory disease Receives: Biological: blood test |
What is being measured
The primary outcome is the main question the study is designed to answer.
prevalence of HLA B leader in both groups
prevalence of HLA B leader in patients with psoriatic rheumatism compared to the healthy group by autoimmune disease
Measured: 1 year
Secondary outcomes (2)
Prevalence of HLAB27 gene in both groups
Prevalence of HLAB27 gene in patients with psoriatic rheumatism compared to the healthy group free from autoimmune disease
Measured: 1 year
prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism patient group
prevalence of the HLAB27/ HLA b Leader gene in different forms of psoriatic rheumatism in patients with different disease conditions
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Jul 2026
- Study start6 May 2025
- Primary completionSep 2026 (estimated)
- Study completionSep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Psoriatic ArthritisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 658 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire, Amiens
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07718815
- Sponsor's protocol ID
- PI2024_843_0115
- Acronym
- HLABLRP
- Status last verified
- Jul 2026
- First submitted
- 16 Jul 2026
- Last updated
- 22 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No